NASDAQ:SLDB - Solid Biosciences Stock Price, Forecast & News

Solid Biosciences trades on the NASDAQ under the ticker symbol "SLDB."

Solid Biosciences Inc (NASDAQ:SLDB) issued its quarterly earnings results on Wednesday, August, 14th. The company reported ($0.76) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($0.81) by $0.05. View Solid Biosciences' Earnings History.

Solid Biosciences is scheduled to release their next quarterly earnings announcement on Wednesday, March 11th 2020. View Earnings Estimates for Solid Biosciences.

8 brokers have issued 12-month price targets for Solid Biosciences' shares. Their forecasts range from $2.00 to $22.00. On average, they expect Solid Biosciences' share price to reach $9.86 in the next year. This suggests a possible upside of 197.8% from the stock's current price. View Analyst Price Targets for Solid Biosciences.

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Solid Biosciences in the last year. There are currently 2 sell ratings, 1 hold rating and 5 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Solid Biosciences.

News articles about SLDB stock have trended extremely negative recently, according to InfoTrie Sentiment Analysis. The research group scores the sentiment of media coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Solid Biosciences earned a news impact score of -4.0 on InfoTrie's scale. They also gave news articles about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the stock's share price in the near future. View News Stories for Solid Biosciences.

Some companies that are related to Solid Biosciences include Agenus (AGEN), Voyager Therapeutics (VYGR), Translate Bio (TBIO), Compugen (CGEN), Autolus Therapeutics (AUTL), Adaptimmune Therapeutics (ADAP), Precision BioSciences (DTIL), PDL BioPharma (PDLI), BioCryst Pharmaceuticals (BCRX), Scholar Rock (SRRK), Cabaletta Bio (CABA), Harpoon Therapeutics (HARP), Gritstone Oncology (GRTS), Tcr2 Therapeutics (TCRR) and Cellular Biomedicine Group (CBMG).

Based on aggregate information from My MarketBeat watchlists, some companies that other Solid Biosciences investors own include Inovio Pharmaceuticals (INO), Sarepta Therapeutics (SRPT), Amarin (AMRN), Fate Therapeutics (FATE), Selecta Biosciences (SELB), Crispr Therapeutics (CRSP), Exelixis (EXEL), Zynerba Pharmaceuticals (ZYNE), Agile Therapeutics (AGRX) and Catalyst Pharmaceuticals (CPRX).

(SLDB) raised $130 million in an initial public offering on Friday, January 26th 2018. The company issued 7,000,000 shares at a price of $18.00-$19.00 per share. J.P. Morgan, Goldman Sachs and Leerink Partners served as the underwriters for the IPO and Nomura and Chardan were co-managers.

Solid Biosciences' stock is owned by many different of retail and institutional investors. Top institutional shareholders include Boxer Capital LLC (2.24%), State Street Corp (0.76%), Spark Investment Management LLC (0.30%), Charles Schwab Investment Management Inc. (0.19%), Goldman Sachs Group Inc. (0.18%) and UBS Group AG (0.16%). Company insiders that own Solid Biosciences stock include Boxer Capital, Llc, Ilan Ganot, Joel Solomon Zev Schneider, Jorge Armando Quiroz, Juan Andrey Zarur, Life Sciences Maste Perceptive, Matthew Bennett Arnold and Pedro Alvaro Amorrortu. View Institutional Ownership Trends for Solid Biosciences.

SLDB stock was sold by a variety of institutional investors in the last quarter, including Boxer Capital LLC, Matisse Capital, Citigroup Inc., Goldman Sachs Group Inc., Charles Schwab Investment Management Inc. and UBS Group AG. Company insiders that have sold Solid Biosciences company stock in the last year include Boxer Capital, Llc and Juan Andrey Zarur. View Insider Buying and Selling for Solid Biosciences.

SLDB stock was acquired by a variety of institutional investors in the last quarter, including Spark Investment Management LLC, State Street Corp, Renaissance Technologies LLC, Alambic Investment Management L.P., Tower Research Capital LLC TRC , Swiss National Bank, Credit Suisse AG and Bank of New York Mellon Corp. View Insider Buying and Selling for Solid Biosciences.

Shares of SLDB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of SLDB stock can currently be purchased for approximately $3.31.

Solid Biosciences has a market capitalization of $152.22 million. The company earns $-74,800,000.00 in net income (profit) each year or ($2.25) on an earnings per share basis. Solid Biosciences employs 111 workers across the globe.View Additional Information About Solid Biosciences.

The official website for Solid Biosciences is http://www.solidbio.com/.

Solid Biosciences' mailing address is 141 PORTLAND STREET FIFTH FLOOR, CAMBRIDGE MA, 02139. The company can be reached via phone at 617-337-4680.